Maverick Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Maverick Therapeutics's estimated annual revenue is currently $775k per year.
- Maverick Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Maverick Therapeutics has 5 Employees.
- Maverick Therapeutics grew their employee count by 0% last year.
Maverick Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Scientist I | Reveal Email/Phone |
Maverick Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Maverick Therapeutics?
Maverick Therapeutics is pioneering the next generation of redirected T-cell targeted immunotherapies. Maverick's highly innovative platform, COBRAâ„¢, is the most advanced bispecific T-cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity.
keywords:N/A
N/A
Total Funding
5
Number of Employees
$775k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Maverick Therapeutics News
In early studies of two therapies presented at the annual meeting of ... Bristol Myers Squibb, Merck and Maverick Therapeuticsthe latter...
Takeda hopes these therapies could help make tumors more receptive to other ... Merck and Maverick Therapeuticsthe latter two announced alongside a $13...
DPR is a consultant/advisory board member for MPM Capital, Gritstone Oncology, Oncorus, Maverick Therapeutics, 28/7 Therapeutics,...
Other Companies in Brisbane
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.6M | 5 | -17% | N/A |
#2 | $0.5M | 6 | -71% | N/A |
#3 | $0.4M | 6 | N/A | N/A |
#4 | $0.4M | 6 | N/A | N/A |
#5 | $0.4M | 6 | N/A | N/A |